Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials
- Resource Type
- Article
- Source
- In
American Heart Journal December 2022 254:88-101 - Subject
- Language
- ISSN
- 0002-8703